2023年4月30日

Relievant Medsystems——一个公司致力于把vertebrogenic疼痛的诊断和治疗,一种慢性下腰痛(CLBP)宣布,它已经完成了关闭的G系列融资5000万美元。资金是由新投资者盟友桥组与现有投资者参与“奋进号”愿景,Vensana首都Lightstone企业,新企业Associates迦南合作伙伴和morgenthal的企业。在美国有3000万人患有慢性下腰痛和1 6可能vertebrogenic疼痛,这是一个不同类型的慢性下腰痛引起的椎体终板损伤、椎间盘和椎体之间的接口。中间的病人通常有疼痛的腰,弯腰时加重,长时间坐着,或者当他们是活跃的。医生能够确认病人的痛苦是通过观察Modic vertebrogenic变化,生物标志物在标准核磁共振表明炎症在椎体终板。Relievant Medsystems“微创Intracept过程被称为唯一fda治疗慢性vertebrogenic下腰痛,使用有针对性的射频能量阻止basivertebral神经(BVN)传递疼痛信号到大脑。和执行的过程通常是在一个门诊手术中心,大约需要1小时。和现有数据的基础上,患者通常经验最少需要术后疼痛和一般快速的恢复时间。患者经常感到疼痛治疗的2周内Intracept过程。关键引用:“这大量额外的资金可以让我们进一步加速努力改变vertebrogenic疼痛的诊断和治疗。 We are thrilled to see strong support from Ally Bridge Group and existing investors in this oversubscribed round as we expand Intracept adoption and make this treatment available to more patients and physicians.” — Tyler Binney, President and CEO of Relievant Medsystems “We are pleased to join the investor syndicate supporting Relievant. We have been impressed by the company’s novel and clinically proven technology and accelerating commercial traction and adoption. We are excited to partner with the company on its journey to provide relief for the millions of patients in the U.S. suffering from chronic low back pain indicated for Relievant’s Intracept Procedure.” — Kevin Reilly, a Managing Director at Ally Bridge Group Trending on Pulse 2.0